bottom for a lot of reasons. Usually, however, investors will assume that something is fundamentally unsound about the store or the company. Perhaps its business model is flawed, or its product has grown unpopular – these and many more factors can drive the down. But sometimes, perhaps just as often, a will fall when there is no underlying unsoundness. A spate of bad news, a quarter that , or a bad sales month – fleeting factors like these might push a stock down but will also frequently reverse themselves quickly. For a savvy investor, that window between the dropping and the causal factor changing can mark an opportunity. Plenty of analysts are willing to recommend stocks that may seem to be running down – but have the potential for solid gains in the near- to mid-term. Using the TipRanks database, we . These are equities with and enough upside potential to convince the analysts that what goes down might come up.
Headquartered in Paris and with offices in New York City and Raleigh, North Carolina, Cellectis is a cutting-edge biopharma company engaged in cancer immunotherapy research. The company is developing chimeric antigen receptor (CAR) T-cells, a technology that uses the patient’s to combat cancer cells. Cellectis’ proprietary gene-editing tech is geared to develop CAR-T as an ‘off the shelf’ treatment. Shares in CLLS peaked at $34 in January of this , and since then, the stock has slid 58%. This slide has come even as the company’s research pipeline and partnerships are showing progress.
The company’s leading treatment candidates are the UCARTs, universal chimeric antigen T-cells, a class of new. Each UCART is an allogeneic CAR T-cell intended for wide distribution. Cellectis has four in the development pipeline, with the leading candidate, UCART19, under development in partnership with Servier and Allogene. As part of the partnerships, Allogene is studying its version CD19. Born in the US, this study has shown success as a proof-of-concept for the UCARTs. In Cellectis’ analysis, UCART19 showed a 55% overall patient survival during its Phase 1 against hematological malignancies.
, UCART22 stands out. This candidate, under investigation as leukemia treatment, specifically relapsed and refractory B-cell acute lymphoblastic leukemia, is currently undergoing a Phase 1 dose-escalation study, with results expected at the end of this calendar . During the first quarter of this , Cellectis’ new drug candidate manufacturing facility, under construction in Raleigh, North Carolina, showed progress toward its go-live scheduled for late this year. The facilities laboratories have gone online, and method transfer and qualification activities are ongoing.
Despite the hefty losses incurred so far in 2021, Baird analyst Brian Skorney year ahead. (To watch Skorney’s track record, click here.) “We continue to believe in the long-term prospects of allogeneic CAR-T and note that recently announced data from Cellectis’ partner Allogene’s CD19 CAR-T program provides encouraging signals that TALEN-derived allogeneic products may be able to match the clinical profile seen with the autologous first-generation products.in CLLS shares. The analyst rates the stock an Outperform (i.e., Buy), and his $39 price target suggests it has a 170% upside potential in the
Allogene has also started to study a consolidation regimen that can further increase the number of responders. By demonstrating clinical efficacy akin to autologous products, we believe Allogene’sproof-of-concept for the UCART platform,” Skorney opined. Overall, this stock’s Strong Buy consensus rating is built on five recent reviews, which break down 4 to 1 in favor of Buy versus Hold. The at $14.44, and their $37.33 average target implies a one-year upside of ~159%. (See CLLS stock analysis on TipRanks)
Shifting gears, we’ll turn our attention to one of the Chinese internet’s major search engines, Youdao. This company, established 14 years ago, is the featured search the full range of search options that web surfers have come to expect: news, music, images, websites, blogs – the whole 9 yards. Youdao also hosts an asset for Chinese as an online dictionary in Chinese and Chinese-English writing. Youdao’s web products include tools.
Shares in DAO peaked last August when they hit $46. The stock has been down since then, losing 57% of its share value. This loss has comequarterly revenues. For the first quarter of 2021, DAO showed $204.5 line (1.3 billion RMB), up 22% sequentially and an even more impressive 163% year-over-year. The company saw strong growth in its online learning services and products, which grew 156% and 279% year-over-year, resine grew 40% yoy, and gross billings increased by 55%. The company’s gross margin increased from 43% in the year-ago quarter to 57% in Q1.
Covering this stock for Nomura, analyst Jessie Xu sees the company profiting from increased web user traffic and a diverse range of products. “We expect the momentum to continue given the pipeline. We also see an upside in monetizing other online courses (including China University MOOC and NetEase Cloud Classroom) in the long term,” Xu noted. The analyst added, “DAO currently trades at 2x 2022F P/S, vs. major peers’ P/S range of 3-4x (our estimate), which is the lowest level among its China online K12 peers… We expect DAO to outperform peers… as we believe it is relatively resilient to regulatory changes.”
Xu’s Buy rating on the stock comes with a $30 price target that implies room for 51% growth this. (To watch Xu’s track record, click here) Overall, Youdao has three recent reviews on file, and all are positive – making the Strong Buy consensus unanimous. The at $19.91 and hold an average price target of $32.33, giving a potential upside of ~62% for the year ahead. (See Youdao’s stock analysis at TipRanks) To find good ideas for at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.